Study Comparing Fosaprepitant and Ondansetron for Treating Nausea and Vomiting in Adults in the Emergency Department

What this Trial Is About

Nausea and vomiting NV are common conditions affecting millions of adults each year, leading many to seek emergency department ED care. Researchers are evaluating fosaprepitant, a newer antiemetic drug that blocks neurokinin NK-1 in the brain, to compare its effectiveness and side effects against the standard antiemetic ondansetron. Fosaprepitant is currently approved only for chemotherapy-induced and postoperative NV, and this study aims to determine if it may better serve patients with NV in the ED setting. Participants will be randomly assigned to receive either fosaprepitant 150 mg or ondansetron 4 mg, both given intravenously over 15 minutes. This double-blind trial compares these two medications to assess their ability to relieve nausea and vomiting and monitor adverse events within 2 hours after administration. The study includes adults presenting to the ED with NV, some of whom may have previously received antiemetics but remain symptomatic after 2 hours. During the study, participants will be monitored for relief from NV and any new symptoms within 2 hours following medication. Additional assessments include sustained relief at 24 hours, ED length of stay, and patient medication preference for future episodes. Follow-up communication will be conducted by phone. The total study duration allows careful evaluation of treatment efficacy and tolerability while ensuring participant safety and convenience.

Antiemetic Fosaprepitant To Remedy Nausea and Vomiting